Kenvue Inc. (NYSE:KVUE) Receives Consensus Recommendation of “Hold” from Brokerages

Kenvue Inc. (NYSE:KVUE) has been assigned an average recommendation of “Hold” from the sixteen research firms that are currently covering the firm, Marketbeat.com reports. Thirteen investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $19.3333.

A number of research analysts have recently issued reports on KVUE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Wednesday, April 8th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $23.00 to $18.00 in a research note on Friday, January 30th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Elyxium Wealth LLC bought a new position in Kenvue in the 4th quarter worth approximately $26,000. Physician Wealth Advisors Inc. raised its position in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. Cornerstone Planning Group LLC raised its position in Kenvue by 705.2% in the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after purchasing an additional 1,361 shares during the last quarter. NBT Bank N A NY raised its position in Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after purchasing an additional 1,006 shares during the last quarter. Finally, MV Capital Management Inc. bought a new position in Kenvue in the 4th quarter worth approximately $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $17.59 on Friday. Kenvue has a 1 year low of $14.02 and a 1 year high of $24.61. The firm has a 50 day moving average of $17.65 and a 200-day moving average of $17.24. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $33.76 billion, a P/E ratio of 20.69, a price-to-earnings-growth ratio of 4.02 and a beta of 0.55.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.76%. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the previous year, the company posted $0.24 earnings per share. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kenvue will post 1.1 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be given a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date is Wednesday, May 13th. Kenvue’s payout ratio is 107.79%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.